LIG1 is a synthetic lethal target in BRCA1 mutant cancers.

Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on poly(ADP-ribose) polymerase (PARP) inhibitors, which are subject to high rates of innate or acquired resistance in patients. Here, we used CRISPR/Cas9-based screening to identify DNA Ligase I (LIG1) as a novel target for synthetic lethality in BRCA1-mutated cancers. Publicly available data supported LIG1 hyperdependence of BRCA1-mutant cells across a variety of breast and ovarian cancer cell lines.

Search for CP-Violating Neutrino Nonstandard Interactions with the NOvA Experiment.

This Letter reports a search for charge-parity (CP) symmetry violating nonstandard interactions (NSI) of neutrinos with matter using the NOvA Experiment, and examines their effects on the determination of the standard oscillation parameters. Data from ν_{μ}(ν[over ¯]_{μ})→ν_{μ}(ν[over ¯]_{μ}) and ν_{μ}(ν[over ¯]_{μ})→ν_{e}(ν[over ¯]_{e}) oscillation channels are used to measure the effect of the NSI parameters ϵ_{eμ} and ϵ_{eτ}. With 90% CL the magnitudes of the NSI couplings are constrained to be |ϵ_{eμ}|≲0.

An assessment of a GMP schistosomiasis vaccine (SchistoShield).

Introduction: Schistosomiasis is a neglected tropical disease that puts over 200 million people at risk, and prevention options are sparse with no approved vaccine. Our vaccine candidate, SchistoShield, is based on an approximately 87 kDa large subunit of calcium activated neutral protease - termed Sm-p80 - combined with a potent TLR4 agonist-based adjuvant. SchistoShield has been shown to prevent disease throughout the parasitic life cycle - including egg, juvenile, and adult worm stages - in numerous animal models up to and including baboons.

Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination.

Unlabelled: Serogroup B (MenB) is the leading cause of invasive meningococcal disease among adolescents and young adults in the United States. The US Advisory Committee on Immunization Practices (ACIP) recommends MenB vaccination based on shared clinical decision making between patients and providers. However, suboptimal understanding of these recommendations could contribute to low vaccination awareness and coverage.